213 related articles for article (PubMed ID: 14703068)
21. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.
Nishimura R; Rai Y; Matsuo F; Anan K; Hara S; Imamura S; Itoyanagi N; Kato M; Okido M; Kudaka M; Ishikawa E; Kamada Y; Watanabe R; Shirouzu M; Mitsuyama S; Takamatsu Y; Tamura K
Anticancer Res; 2012 Aug; 32(8):3259-65. PubMed ID: 22843900
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
25. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
26. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.
Hirano A; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Okabe T; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2006; 26(1B):581-4. PubMed ID: 16739324
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
Chan A; McGregor SR
Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
29. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
31. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
Parissenti AM; Chapman JA; Kahn HJ; Guo B; Han L; O'Brien P; Clemons MP; Jong R; Dent R; Fitzgerald B; Pritchard KI; Shepherd LE; Trudeau ME
Breast Cancer Res Treat; 2010 Jan; 119(2):347-56. PubMed ID: 19771508
[TBL] [Abstract][Full Text] [Related]
32. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
34. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer.
Varga Z; Caduff R; Pestalozzi B
Virchows Arch; 2005 Feb; 446(2):136-41. PubMed ID: 15650840
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Dawood S; Gonzalez-Angulo AM; Peintinger F; Broglio K; Symmans WF; Kau SW; Islam R; Hortobagyi GN; Buzdar AU
Cancer; 2007 Sep; 110(6):1195-200. PubMed ID: 17647266
[TBL] [Abstract][Full Text] [Related]
36. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Espinosa E; Morales S; Borrega P; Casas A; Madroñal C; Machengs I; Illarramendi JA; Lizón J; Moreno JA; Belón J; Janáriz J; de la Puente M; Checa T; Mel JR; González Barón M
Cancer Chemother Pharmacol; 2004 Dec; 54(6):546-52. PubMed ID: 15316749
[TBL] [Abstract][Full Text] [Related]
38. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
40. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]